Multivariate results showed that AFP (HR, 1.818; 95% CI: 1.054-3.316; p= 0.032), ALB (HR, 0.953; 95% CI: 0.910-0.998; p= 0.041), adjuvant therapy (HR, 0.477; 95% CI: 0.306-0.745; p= 0.001), tumor diameter (HR, 2.389; 95% CI: 1.078-5.607; p= 0.032), PVTT (HR, 2.765; 95% CI: 1.303-5.297; p= 0.008) and TACE (HR, 0.587; 95% CI: 0.372-0.927; p= 0.022) was a significant factor associated with OS in HCC patients with high-risk recurrence factors (Table 2). This evidence concerns the gene ALB and hepatocellular carcinoma.